These reports showed that the PI3K/AKT/mTOR pathway may be a new target for treatment in MPN, in accordance with mTOR’s essential role for expansion of CD34+ cells during myelopoiesis [41]. This evidence concerns the gene AKT1 and myeloproliferative neoplasm.